Please login to the form below

Not currently logged in
Email:
Password:

Linzess

This page shows the latest Linzess news and features for those working in and with pharma, biotech and healthcare.

China approves Ironwood Pharma’s IBS treatment

China approves Ironwood Pharma’s IBS treatment

Coincides with AZ's Mark Mallon taking over as CEO. Ironwood Pharmaceuticals’ irritable bowel syndrome treatment Linzess has gained approval in China, opening up a market of up to 14m adults ... Mark Mallon, CEO, Ironwood Pharmaceuticals and Cyclerion.

Latest news

More from news
Approximately 2 fully matching, plus 5 partially matching documents found.

Latest Intelligence

  • Oral biologics delivery still elusive Oral biologics delivery still elusive

    years. Among a newer generation of orally-delivered peptides is Ironwood Pharma's peptide drug Linzess/Constella (linaclotide) - which debuted in 2012 for constipation associated with irritable bowel syndrome. ... All eyes will now be on the performance

  • Pharma deals during April 2014 Pharma deals during April 2014

    Forest is building a leading position in the $38bn gastroenterology (GI) market adding eluxadoline to its broader GI portfolio including Linzess. Actavis has consented to Forest's acquisition of Furiex. The

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Ironwood appoints Edward Owens to board Ironwood appoints Edward Owens to board

    Owens is a former partner at investments advisor Wellington Management, and joins the US-based biopharma at a time of growth following the approval of Linzess (linaclotide) in the US for ... The execution of a successful launch of Linzess should provide

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
mXm Medical Communications

mXm Medical Communications meets the needs of pharmaceutical marketers and medics who require a highly experienced, bespoke service from their...

Latest intelligence

Brain power: fresh approaches to Alzheimer’s drug discovery
New alliances are learning from past mistakes and breaking down research barriers...
Genomics integration: can the NHS rise to the challenge?
Experts gather to discuss the UK’s genomic landscape...
London
“Brexit has been a catalyst for UK clinical research... it’s turbocharged change”
The UK clinical trials environment has been transformed in recent years – but can it really buck Brexit’s risks and uncertainties?...

Infographics